BioCryst Pharmaceuticals is trading 7.1% up at $10.43 in pre-market sessions after JPMorgan resumed coverage with a Neutral rating and a $12 price target.
- The analyst resumption highlights a strong focus on the company's rare-disease portfolio, which has been a primary driver of recent investor interest.
- The move follows a period of positive sentiment from other Wall Street analysts, contributing to the stock's momentum in early trading.